ReviewEuropean respiratory review : an official journal of the European Respiratory Society2024
Pulmonary veno-occlusive disease: illustrative cases and literature review.
Review in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Alkylating Agent-Induced FANCL Impairment Damages Pulmonary Arterial, Venous, and Microvascular Endothelial Cells and Predisposes to PAH/PVOD.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation.Signal transduction and targeted therapy · 2026Review
- Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Pulmonary veno-occlusive disease after immune checkpoint inhibitor therapy: an autopsy case report.European heart journal. Case reports · 2026Article
- Small Pulmonary Artery and Vein Volumes Independently Predict Oxygen Desaturation in Smokers.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026Article
- Broiler Ascites Syndrome as a Potential Spontaneous Animal Model for Human Pulmonary Arterial Hypertension: A Narrative Review.Life (Basel, Switzerland) · 2026Review
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Pulmonary veno-occlusive disease: Insights from animal models.Vascular pharmacology · 2025Review
- Drugs and toxins associated with pulmonary arterial hypertension: from established culprits to novel threats.ERJ open research · 2025Review
- Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management.Advances in respiratory medicine · 2025Review
- Essential role of protein kinase R in the pathogenesis of pulmonary veno-occlusive disease.JCI insight · 2025Article
- Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization.Nature communications · 2025Article
- DNA Damage in Pulmonary Arterial Hypertension and Veno-Occlusive Disease-FANCL as Dual Rescue?American journal of respiratory and critical care medicine · 2025Article
- Cobalamin C deficiency: a rare but treatable genetic cause of pulmonary hypertension.Orphanet journal of rare diseases · 2025Article
- Pediatric Pulmonary Hypertension Associated With Treatment of Myeloproliferative Disorders and Malignant Tumors.Pulmonary circulation · 2025Article
- Pulmonary veno-occlusive disease: a clinical review.Breathe (Sheffield, England) · 2025Review
- Article
- Definition, classification and diagnosis of pulmonary hypertension.The European respiratory journal · 2024Article
- From the microscopic to the macroscopic: clinical-radiological-pathological correlation in pulmonary hypertension.European respiratory review : an official journal of the European Respiratory Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary veno-occlusive disease (PVOD), also known as "pulmonary arterial hypertension (PAH) with overt features of venous/capillary involvement", is a rare cause of PAH characterised by substantial small pulmonary vein and capillary involvement, leading to increased pulmonary vascular resistance and right ventricular failure. Environmental risk factors have been associated with the development of PVOD, such as occupational exposure to organic solvents and chemotherapy, notably mitomycin. PVOD may also be associated with a mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.